Literature DB >> 24151181

Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk.

Emily R Fisher1, Michael R Hayden.   

Abstract

There is uncertainty surrounding the accuracy of prevalence estimates for Huntington's disease (HD). The aims of this study were to provide a best estimate of the prevalence and population at risk for HD in the province of British Columbia (BC), Canada, in 2012. HD patients with a clinical and/or genetic diagnosis of HD and individuals at risk for HD were ascertained from multiple sources. Clinical and genetic data were obtained from all available medical, social service, and genetic testing records. Six hundred and thirty-one HD patients and 3,763 individuals at 25% or 50% risk for HD were identified. Prevalence of HD was estimated at 13.7 per 100,000 (95% confidence interval [CI]: 12.6-14.8 per 100,000) in the general population, and 17.2 per 100,000 (95% CI: 15.8-18.6 per 100,000) in the Caucasian population. The population at 25% to 50% risk was estimated at 81.6 per 100,000 (95% CI: 79.0-84.2 per 100,000) individuals. These figures suggest there may be up to 4,700 individuals affected with HD and 14,000 at 50% risk for HD in Canada as well as up to 43,000 individuals affected with HD and 123,000 at 50% risk for HD in the United States. This is the first direct assessment of HD epidemiology in Canada in over three decades. These findings suggest that underascertainment may have led to previous underestimates of prevalence, namely, in Caucasian populations, and will aid in the planning of appropriate resource allocation and service delivery for the HD community.
Copyright © 2013 Movement Disorder Society.

Entities:  

Keywords:  Huntington disease; ascertainment; epidemiology; population at risk; prevalence

Mesh:

Year:  2013        PMID: 24151181     DOI: 10.1002/mds.25717

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  42 in total

Review 1.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

2.  Case report: concurrent Wilson disease and Huntington disease: lightning can strike twice.

Authors:  Andrea Zanko; Liane Abrams
Journal:  J Genet Couns       Date:  2014-11-08       Impact factor: 2.537

3.  Targeting the low-hanging fruit of neurodegeneration.

Authors:  Amanda R Mason; Adam Ziemann; Steven Finkbeiner
Journal:  Neurology       Date:  2014-10-14       Impact factor: 9.910

Review 4.  Huntington's disease: the coming of age.

Authors:  Mritunjay Pandey; Usha Rajamma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 5.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

6.  CAG repeat size in Huntingtin alleles is associated with cancer prognosis.

Authors:  Morgane Sonia Thion; Sophie Tézenas du Montcel; Jean-Louis Golmard; Sophie Vacher; Laure Barjhoux; Valérie Sornin; Cécile Cazeneuve; Ivan Bièche; Olga Sinilnikova; Dominique Stoppa-Lyonnet; Alexandra Durr; Sandrine Humbert
Journal:  Eur J Hum Genet       Date:  2016-03-16       Impact factor: 4.246

Review 7.  Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.

Authors:  Deepa Dash; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

8.  The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America.

Authors:  Chris Kay; Indira Tirado-Hurtado; Mario Cornejo-Olivas; Jennifer A Collins; Galen Wright; Miguel Inca-Martinez; Diego Veliz-Otani; Maria E Ketelaar; Ramy A Slama; Colin J Ross; Pilar Mazzetti; Michael R Hayden
Journal:  Eur J Hum Genet       Date:  2016-12-21       Impact factor: 4.246

Review 9.  Huntington's Disease: Relationship Between Phenotype and Genotype.

Authors:  Yi-Min Sun; Yan-Bin Zhang; Zhi-Ying Wu
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

10.  Thinking about the end of life: a common issue for patients with Huntington's disease.

Authors:  Suzanne J Booij; Aad Tibben; Dick P Engberts; Johan Marinus; Raymund A C Roos
Journal:  J Neurol       Date:  2014-09-02       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.